C-reactive protein and transesophageal echocardiographic markers of thromboembolism in patients with atrial fibrillation

International Journal of Cardiology

Volumn 159, Issue 1, 2012, Pages 40-46

  Ederhy, Stéphane ^a   Di Angelantonio, Emanuele ^a   Dufaitre, Ghislaine ^a   Meuleman, Catherine ^a   Masliah, Joelle ^b   Boyer Chatenet, Louise ^a   Boccara, Franck ^a   Cohen, Ariel ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Atrial fibrillation; C reactive protein; Stroke risk stratification; Transesophageal echocardiography

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; AORTA ATHEROSCLEROSIS; ARTICLE; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; FRAMINGHAM RISK SCORE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HUMAN; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; REFERENCE VALUE; RISK ASSESSMENT; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; ULTRASOUND SCANNER;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 84863780716     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.02.020     Document Type: Article

References (40)

1. Fuster V, Rydén LE, Cannom DS, et al. JL ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854-906. (Pubitemid 44175743)
2. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
3. Leung DY, Davidson PM, Cranney GB, Walsh WF. Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am J Cardiol 1997;79:626-9. (Pubitemid 27143167)
4. Stöllberger C, Chnupa P, Kronik G, et al. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. Ann Intern Med 1998;128:630-8.
5. Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999;12:1088-96.
6. Goldman ME, Pearce LA, Hart RG, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999;12:1080-7.
7. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998;128: 639-47.
8. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10. (Pubitemid 37553570)
9. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-91. (Pubitemid 33139098)
10. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4. (Pubitemid 27344221)
11. Conway DS, Buggins P, Hughes E, Lip GYl. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J AmColl Cardiol 2004;43:2075-82. (Pubitemid 38686805)
12. Conway DS, Buggins P, Hughes E, Lip GY. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol 2004;93:1368-73 A1366.
13. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007;38:1229-37. (Pubitemid 351664238)
14. Di Angelantonio E, Ederhy S, Benyounes N, Janower S, Boccara F, Cohen A. Comparison of transesophageal echocardiographic identification of embolic risk markers in patients with lone versus non-lone atrial fibrillation. Am J Cardiol 2005;95:592-6. (Pubitemid 40255246)
15. Lang RM, Bierig M, Devereux RB, et al. ecommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63. (Pubitemid 41821197)
16. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994;23:961-9. (Pubitemid 24090884)
17. Mügge A, Kühn H, Nikutta P, Grote J, Lopez JA, Daniel WG. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 1994;23:599-607. (Pubitemid 24074936)
18. Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994;331:1474-9. (Pubitemid 24356305)
19. Ryan T, Armstrong WF, Khandheria BK. Task force 4: training in echocardiography endorsed by the American Society of Echocardiography. J Am Coll Cardiol 2008;51:361-7.
20. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
21. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis 1995;5:147-57.
22. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. (Pubitemid 32537350)
23. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999;30:1223-9. (Pubitemid 29259178)
24. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049-56. (Pubitemid 37430445)
25. Lip GY, Rudolf M. The new NICE guideline on atrial fibrillation management. Heart 2007;93:23.
26. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:546S-92S. (Pubitemid 351892972)
27. European Heart Rhythm Association; European Association for Cardio-Thoracic SurgeryCamm AJ, Kirchhof P, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
28. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
29. Kleemann T, Becker T, Strauss M, Schneider S, Seidl K. Prevalence and clinical impact of left atrial thrombus and dense spontaneous echo contrast in patients with atrial fibrillation and low CHADS2 score. Eur J Echocardiogr 2009;10: 383-8.
30. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008;51:810-5. (Pubitemid 351253746)
31. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost 2010;103:833-40.
32. Ederhy S, Dufaitre G, Boyer-Chatenet L, et al. Should all patients with non-valvular atrial fibrillation be anticoagulated? Int J Cardiol 2010;143:8-15.
33. Black IW, Stewart WJ. The role of echocardiography in the evaluation of cardiac source of embolism: left atrial spontaneous echo contrast. Echocardiography 1993;10:429-39. (Pubitemid 23215431)
34. Kwaan HC, Sakurai S, Wang J. Rheological abnormalities and thromboembolic complications in heart disease: spontaneous echo contrast and red cell aggregation. Semin Thromb Hemost 2003;29:529-34. (Pubitemid 37352652)
35. Kamp O, Verhorst PM, Welling RC, Visser CA. Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. Eur Heart J 1999;20:979-85. (Pubitemid 29281446)
36. Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol 1994;24:755-62. (Pubitemid 24295753)
37. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998;31:1622-6. (Pubitemid 28273307)
38. Bernhardt P, Schmidt H, Hammerstingl C, Lüderitz B, Omran H. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol 2005;45:1807-12. (Pubitemid 40789939)
39. Thambidorai SK, Parakh K, Martin DO, et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004;94:805-7. (Pubitemid 39221509)
40. Shewan LG, Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.